| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-12-20 | OPN-305 | second-line lower (Low and intermediate-1) risk myelodysplastic syndrome | 1-2 | Opsona Therapeutics (Ireland) | Cancer - Oncology |
| 2016-12-20 | GLPG1837 | cystic fibrosis with the G551D mutation | 2 | Galapagos (Belgium) | Rare diseases - Genetic diseases |
| 2016-12-19 | volanesorsen (phosphorothioate oligonucleotide targeted to apolipoprotein C-III - IONIS-APOCIIIRx) | hypertriglyceridemia | 3 | Akcea Therapeutics (USA - CA), a subsidiary of Ionis Pharmaceuticals (USA - CA) | Metabolic diseases |
| 2016-12-18 | LOXO- 101 (larotrectinib - (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate) | adult solid tumors | 1 | Loxo Oncology (USA - CT) | Cancer - Oncology |
| 2016-12-16 | BGB324 | acute myeloid leukaemia | 1b-2 | BerGenBio (Norway) | Cancer - Oncology |
| 2016-12-16 | BioChaperone Lispro® | type 1 diabetes mellitus | 1 | Adocia (France) Eli Lilly (USA - IN) | Metabolic diseases |
| 2016-12-16 | TG-1101 (ublituximab) and ibrutinib | chronic lymphocytic leukemia (CLL) | 2 | TG Therapeutics (USA - NY) | Cancer - Oncology |
| 2016-12-14 | NeuVax™ (nelipepimut-S) | ductal breast carcinoma in situ | 2 | Galena Biopharma (USA - OR) | Cancer - Oncology |
| 2016-12-14 | MIV-323 | Respiratory Syncytial Virus (RSV) infection | Medivir (Sweden) | Infectious diseases | |
| 2016-12-13 | GTL001/ProCervix® | treatment of adult women already infected with human papillomavirus (HPV) genotype 16 or 18 | 2 | Genticel (France) | Infectious diseases |
| 2016-12-13 | Sollpura™ (liprotamase) | cystic fibrosis | Anthera Pharmaceuticals (USA - CA) | Rare diseases - Genetic diseases | |
| 2016-12-13 | RHB-104 (clarithromycin, clofazimine and rifabutin) | Crohn's disease | 3 | RedHill Biopharma (Israel) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-12-13 | MOR208 and idelalisib | relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | 2 | MorphoSys (Germany) | Cancer - Oncology |
| 2016-12-13 | dasiglucagon (ZP4207) | type 1 diabetes | 2 | Zealand Pharma (Denmark) | Metabolic diseases |
| 2016-12-12 | pegpleranib in combination with Lucentis® (ranibizumab) | neovascular age-related macular degeneration | 3 | Novartis (Switzerland) | Ophtalmological diseases |
| 2016-12-12 | ATA 129 (EBV-CTL) | rituximab-refractory EBV-Associated Post Transplant Lymphoproliferative Disorder (EBV-PTLD) | 3 | Atara Biotherapeutics (USA - CA) | Infectious diseases - Transplantation |
| 2016-12-12 | GLPG0634 (filgotinib) | Crohn's disease | 2 | Galapagos (Belgium) AbbVie (USA - IL) | Autoimmune diseases - Inflammatory diseases - Digestive diseases |
| 2016-12-12 | C16G2 | dental caries | 2 | C3J Therapeutics (USA - CA) | Infectious diseases |
| 2016-12-12 | BMN 111 (vosoritide) | achondroplasia | 3 | Biomarin Pharmaceutical (USA - CA) | Rare diseases - Genetic diseases |
| 2016-12-10 | ABX464 | HIV/Aids | preclinical | Abivax (France) | Infectious diseases |
